Recent Drug Approval/ High Barriers With Limited Competition:
Sevoflurane, the Company’s primary product was approved in May 2007. RxElite has the exclusive US rights to this product, a $400 M market with only two competitors. High barriers to additional competition include manufacturing process patents, limited manufacturing capacity, and unique chemistry expertise requirements.
Distribution Strength and Key Customers:
RxElite has established distribution agreements to over 90% of the US market for generic drugs. Key select customers include Wal-Mart, Walgreens, McKesson, and Cardinal Health.
Aggressive and Full Pipeline:
RxElite has over 10 products in its pipeline. The Company plans to launch new products in each of the next 12 months over the next three years, targeting over $2 Billion in new addressable markets.
For more information, please visit: http://www.qualitystocks.net/partners.php?partnerid=scvoice